For Immediate Release: October 29, 2025 The U.S. Food and Drug Administration (FDA) today announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases. In a new draft guidance, the FDA proposes major updates to simplify biosimilarity studies and reduce unnecessary clinical …
Read More »FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs
